% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stocker:179024,
      author       = {H. Stocker$^*$ and L. Beyer and L. Perna and D. Rujescu and
                      B. Holleczek and K. Beyreuther and J. Stockmann and B.
                      Schöttker$^*$ and K. Gerwert and H. Brenner$^*$},
      title        = {{A}ssociation of plasma biomarkers, p-tau181, glial
                      fibrillary acidic protein, and neurofilament light, with
                      intermediate and long-term clinical {A}lzheimer's disease
                      risk: {R}esults from a prospective cohort followed over 17
                      years.},
      journal      = {Alzheimer's and dementia},
      volume       = {19},
      number       = {1},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2022-00406},
      pages        = {23},
      year         = {2023},
      note         = {#EA:C070#LA:C070# / 2023 Jan;19(1):25-35},
      abstract     = {Blood biomarkers for Alzheimer's disease (AD) are the
                      future of AD risk assessment. The aim of this study was to
                      determine the association between plasma-measured
                      phosphorylated tau (p-tau181), glial fibrillary acidic
                      protein (GFAP), and neurofilament light (NfL) levels and
                      risk of clinical AD incidence with consideration to the
                      impact of cardiovascular health.Within a community-based
                      cohort, biomarker levels were measured at baseline using
                      single molecule array technology in 768 participants (aged
                      50-75) followed over 17 years. Associations among biomarkers
                      and AD, vascular dementia, and mixed dementia incidence were
                      assessed.GFAP was associated with clinical AD incidence even
                      more than a decade before diagnosis (9-17 years), while
                      p-tau181 and NfL were associated with more intermediate AD
                      risk (within 9 years). Significant interaction was detected
                      between cardiovascular health and p-tau181/NfL.GFAP may be
                      an early AD biomarker increasing before p-tau181 and NfL and
                      the effect modifying role of cardiovascular health should be
                      considered in biomarker risk stratification.},
      keywords     = {Alzheimer's disease (Other) / blood biomarkers (Other) /
                      cardiovascular risk (Other) / risk stratification (Other) /
                      vascular dementia (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35234335},
      doi          = {10.1002/alz.12614},
      url          = {https://inrepo02.dkfz.de/record/179024},
}